Author:
Li Qingqing,Wang Jing,Wang Zheng-lu,Shen Yuxin,Zhou Qi,Liu Ya-nan,Hu Guo-xin,Cai Jian-ping,Xu Ren-ai
Funder
National Natural Science Foundation of China
National Key Research and Development Program of China
Subject
Pharmacology,General Medicine
Reference27 articles.
1. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study;Loebel;Am. J. Psychiatry,2014
2. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study;Loebel;Am. J. Psychiatry,2014
3. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts;Suppes;J. Psychiatr. Res,2016
4. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity;Ishibashi;J. Pharmacol. Exp. Ther.,2010
5. Evaluating lurasidone as a treatment option for bipolar disorder;Ali;Expert Opin. Pharmacother.,2020